Gene
CHEK2
CHEK2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (26), Actionable biomarkers (2), Trial mentions (119), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CHEK2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 12 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 6 of 8,738 | 0.07% | not measured | |
| 2025 | 10 of 8,875 | 0.11% | not measured | |
| 2024 | 10 of 8,597 | 0.12% | not measured | |
| 2023 | 9 of 8,275 | 0.11% | 36 of 11,460 | 0.31% |
| 2022 | 18 of 8,285 | 0.22% | 46 of 13,598 | 0.34% |
| 2021 | 18 of 8,692 | 0.21% | 50 of 15,045 | 0.33% |
| 2020 | 12 of 7,640 | 0.16% | 30 of 14,459 | 0.21% |
| 2019 | 12 of 7,300 | 0.16% | 35 of 12,159 | 0.29% |
| 2018 | 11 of 6,927 | 0.16% | 25 of 11,854 | 0.21% |
| 2017 | 5 of 6,558 | 0.08% | 22 of 11,595 | 0.19% |
Showing 10 of 37 years.
Assay-provider ledger (26)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 2 | July 15, 2025 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 4 | July 15, 2025 +1 undated |
| QIAGEN | Reagent supplier | Clinical validation | 2 | July 15, 2025 |
| TWIST Bioscience | Reagent supplier | Clinical validation | 1 | July 15, 2025 |
| InVitae | Diagnostic provider | Clinical validation | 2 | February 20, 2019 |
Showing 5 of 26 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CHEK2 oncogenic mutation | OLAPARIB | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| CHEK2 deletion | OLAPARIB | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (119)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06922708 | Trial eligibility (AACT) |
| NCT05033756 | Trial eligibility (AACT) |
| NCT03413995 | Trial eligibility (AACT) |
| NCT03840967 | Trial eligibility (AACT) |
| NCT05129605 | Trial eligibility (AACT) |
Showing 5 of 119 trial mentions.
Target-disease associations (572)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Adamantinomatous Craniopharyngioma | cancer or benign tumor | Cancer Gene Census |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Angiomatous Meningioma | cancer or benign tumor | Cancer Gene Census |
| Appendix Adenocarcinoma | cancer or benign tumor | Cancer Gene Census |
| Appendix Goblet Cell Carcinoid | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 572 associations.
Vendor sourcing (496)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: 0.006%). Predicted Consequence/Location: Missense... | View ClinVar record SCV006585828.2 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The CHEK2 c.1100delC; p.Thr367MetfsTer15 variant (rs555607708) is a well-studied variant that was originally associated with Li-Fraumeni syndrome (Bell 1999)... | View ClinVar record SCV000603087.11 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | CHEK2 | View trial NCT03061188 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma (mixed histology will be acceptable, but pure small cell histology is to... | View trial NCT04288687 |
Showing 5 of 496 sourcing records.
Trial-cited literature (376)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | JCO precision oncology | 2025 | 9 |
| Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial. | JAMA internal medicine | 2025 | 5 |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nature medicine | 2024 | 130 |
| Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | 68 |
Showing 5 of 376 papers.
Protein variant mentions (184)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A267V | 1 | 2015 | PMID 25741868 |
| p.A294G | 1 | 2015 | PMID 25741868 |
| p.A453P | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.A480T | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.A530T | 1 | 2015 | PMID 25741868 |
Showing 5 of 184 variants.
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CARBOPLATIN | Chemical | associate |
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial. | 2024 |
| CETUXIMAB | Chemical | associate |
Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances <i>In Vitro</i> and <i>In Vivo</i> Cytotoxicity in Head and Neck Squamous Cell Carcinoma. | 2017 |
| Artesunate | Chemical | negative_correlate |
Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model. | 2015 |
| Artesunate | Chemical | positive_correlate |
Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. | 2011 |
| Bendamustine | Chemical | positive_correlate |
Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. | 2008 |
Showing 5 of 61 relation assertions.
Organizations publishing (474)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 24 | 2010 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 24 | 2014 to 2024 |
| The University of Texas System | Academic | 20 | 2010 to 2023 |
| University of Washington | Academic | 14 | 2015 to 2022 |
| Mayo Clinic | Hospital | 13 | 2013 to 2023 |
Showing 5 of 474 organizations.
Where CHEK2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
414 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.